Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.52 |
| ▸ | BCHE | P06276 | 5/20 | 0.52 |
| ▸ | APP | P05067 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3118517 | 0.99 | LMNA (0.52) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3109776 | 0.87 | EGFR (0.45) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3121533 | 0.86 | ACHE (0.51) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3118614 | 0.86 | ACHE (0.53) | ACHEBCHEAPPLMNAMEN1 | |
| Hydrochloric Acid SCHEMBL3455528 | 0.78 | TSHR (0.58) | LMNAMEN1KMT2ATSHRHTT | |
| SCHEMBL4863396 | 0.77 | APP (0.73) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3977315 | 0.76 | RAD52 (0.71) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL12175936 | 0.75 | APP (0.74) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3118673 | 0.75 | ACHE (0.60) | ACHEBCHEAPPLMNAMEN1 | |
| SCHEMBL3109794 | 0.75 | ACHE (0.63) | ACHEBCHEAPPLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | ACHE 3180/4885BCHE 2344/4885APP 2989/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | ACHE 3329/4885BCHE 2257/4885APP 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.